Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Stagg

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology|February 11, 2020
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trialRobert L Coleman, Katelyn F Handley, Robert Burger, et al.
Neuro-Oncology|April 16, 2005
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials GroupSarah Kirby, Stan Z Gertler, Warren Mason, et al.
Investigational New Drugs|September 20, 2018
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsAntonio Jimeno, Kathleen N Moore, Michael Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsNiharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2022
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerSiqing Fu, Bradley R Corr, Kerry Culm-Merdek, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF trialLarry A Chinitz, Daniel P Melby, Francis E Marchlinski, et al.
Gynecologic Oncology|June 9, 2019
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancerKathleen N Moore, Camille C Gunderson, Paul Sabbatini, et al.
Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology|February 11, 2020
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trialRobert L Coleman, Katelyn F Handley, Robert Burger, et al.
Neuro-Oncology|April 16, 2005
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials GroupSarah Kirby, Stan Z Gertler, Warren Mason, et al.
Investigational New Drugs|September 20, 2018
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsAntonio Jimeno, Kathleen N Moore, Michael Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsNiharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2022
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerSiqing Fu, Bradley R Corr, Kerry Culm-Merdek, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF trialLarry A Chinitz, Daniel P Melby, Francis E Marchlinski, et al.
Gynecologic Oncology|June 9, 2019
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancerKathleen N Moore, Camille C Gunderson, Paul Sabbatini, et al.
Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Pageof 1